Ligand Pharmaceuticals Incorporated Stock News

In the most recent trading session, Ligand Pharmaceuticals (LGND) closed at $58.84, indicating a +1.19% shift from the previous trading day.

Ligand (LGND) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Following the acquisition, Ligand (LGND) has full ownership rights to berdazimer gel, all assets related to NITRICIL drug delivery technology platform and rights to the Sitavig program.

Ligand (LGND) intends to spin out and merge its subsidiary Pelican with Primordial Genetics to form a new standalone company. Post-merger, it will own a 49.9% stake in this new company.

Ligand Pharmaceuticals Incorporated generates revenue through licensing technologies, contractual fees, and the sale of Captisol, a modified cyclodextrin used in drug development. Captisol has been a

Ligand Pharmaceuticals (LGND) reports second-quarter results as earnings beat the estimates, but sales miss the mark. Management raises the 2023 financial outlook.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND ) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET Company Participants Simon Latimer - Head, Investor Relations Todd Davis - Chief Executive

While the top- and bottom-line numbers for Ligand (LGND) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to

Ligand's (LGND) second-quarter 2023 performance is likely to have been driven by rising royalty revenues on the back of higher growth in sales of drugs developed using its pelican platform.

Ligand Pharmaceuticals ( LGND ) is a $1 billion operator of bio-pharmaceutical acquisitions and development. The San Diego company focuses on developing or acquiring royalty revenue generating bio-pha

Ligand (LGND) announces a $15 million bid in cash to acquire all assets of Novan Inc. along with another $15 million loan as debtor-in-possession financing.

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Ligand Pharmaceuticals (LGND) or Illumina (ILMN). But which of these two stocks is more attra

Here is how to use our new analyst coverage screen to help investors find stocks to buy in July and for the second half of 2023.

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Ligand Pharmaceuticals (LGND) and Illumina (ILMN). But which of these two stocks is more

The article discusses the recent developments and transformation of Ligand Pharmaceuticals. It follows up on a previous article from 12/2022 titled "A New Ligand Is Taking Shape". The focus is on the